Experimental cell treatment shows promise for COVID-19 lung failure
NCT ID NCT04447833
First seen May 25, 2026 · Last updated Jun 18, 2026 · Updated 3 times
Summary
This early-stage study tested a single dose of mesenchymal stromal cells in 7 COVID-19 patients with severe acute respiratory distress syndrome (ARDS) who were on ventilators. The main goal was to check safety, looking for serious side effects like heart problems or blood clots within 10 days. The study also tracked survival and changes in blood cells over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.